A new study published by the University of California – Los Angeles Health Sciences highlighted significant trends in ivermectin prescriptions for human use during and after the COVID-19 pandemic. The research, based on insurance claims from the Milliman MedInsight Emerging Experience Research Database covering 8.1 million patients across all 50 states, analyzed data from January 30, 2020, to June 30, 2023. It found that U.S. outpatient prescriptions for ivermectin increased tenfold above pre-pandemic rates, peaking at over 10 times higher than baseline by August 2021, with nearly three million COVID-related prescriptions issued, totaling $272 million in estimated spending. Usage was notably higher among adults aged 65 and older, being three times greater than those aged 18 to 64, and was particularly elevated in the Southern United States and socially vulnerable neighborhoods. The study also noted that after FDA-authorized COVID-19 medications like Paxlovid became available in March 2022, ivermectin use dropped by 93% through June 2023, with $18 million spent post-March 2022. Additionally, a separate report from Medical Xpress on July 23, 2025, indicated that ivermectin, when added to existing malaria control methods, reduced malaria infection rates significantly in a population-based study, offering potential new applications. These findings suggest ongoing exploration of ivermectin’s role in human health, with further research planned to assess its effectiveness across various conditions.
www.34news.online
www.34news.online
